Table 1.
Percentage of subjects (number of subjects / total number of subjects with evaluable samples) in the RSV-ARTI group with T-cell frequencies above LLoQ with respect to antigen stimulation in PBMC assay | |||||
---|---|---|---|---|---|
RSV-A lysate | RSV-B lysate | F peptides | M2-1 peptides | N peptides | |
CD4+ | |||||
Visit 1 | 41 (11/27) | 26 (7/27) | 0 (0/27) | 0 (0/27) | 0 (0/27) |
Visit 2 | 75 (18/24) | 71 (17/24) | 50 (12/24) | 4 (1/24) | 30 (7/23) |
Visit 2c | 93 (27/29) | 83 (24/29) | 46 (13/28) | 4 (1/28) | 14 (4/28) |
CD8+ | |||||
Visit 1 | 0 (0/22) | 0 (0/22) | 4 (1/23) | 0 (0/23) | 4 (1/24) |
Visit 2 | 5 (1/22) | 5 (1/21) | 4 (1/23) | 23 (5/22) | 24 (5/21) |
Visit 2c | 0 (0/25) | 4 (1/24) | 13 (3/24) | 29 (7/24) | 33 (8/24) |
LLoQ, lower limit of quantification; Visit 1, pre–RSV-season visit; Visit 2, visit when RSV-ARTI was reported; and Visit 2c, convalescence visit about 2 weeks after reporting RSV-ARTI.